SCHEMBL718338

SCHEMBL718338

COc1cccc(-n2cc(C(O)C3CCCCC3)c(C(C)C)n2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPK1 P28482 2/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 1/20 0.37
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NOTUM Q6P988 1/20 0.36
CTSS P25774 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ADORA3 P0DMS8 2/20 0.36
ADORA1 P30542 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718340 0.88 IDO1 (0.41) SMN1; SMN2MEN1ALDH1A1KMT2ATP53
SCHEMBL717877 0.87 BCHE (0.42) BCHEL3MBTL1CYP1A2CYP3A4CYP2C19
SCHEMBL719683 0.84 BCHE (0.42) BCHEL3MBTL1CYP1A2CYP3A4CYP2C19
SCHEMBL719184 0.84 PDE4A (0.43) BCHECYP1A2CYP3A4CYP2C19SMN1; SMN2
SCHEMBL719334 0.84 BCHE (0.40) BCHECYP1A2CYP3A4CYP2C19SMN1; SMN2
SCHEMBL3398378 0.77 BCHE (0.39) BCHEL3MBTL1MAPK1MEN1KMT2A
SCHEMBL720040 0.76 NOTUM (0.46) BCHESMN1; SMN2MEN1ALDH1A1KMT2A
SCHEMBL717876 0.76 IDO1 (0.38) CYP1A2CYP3A4CYP2C19SMN1; SMN2MEN1
SCHEMBL720503 0.74 IDO1 (0.42) SMN1; SMN2MEN1ALDH1A1KMT2ATP53
SCHEMBL716549 0.72 RAB9A (0.40) SMN1; SMN2MEN1ALDH1A1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP BCHE 1649/4885L3MBTL1 4088/4885CYP1A2 774/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP BCHE 1649/4885L3MBTL1 4088/4885CYP1A2 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.